Advertisement|Remove ads.

bioAffinity Technologies, Inc. (BIAF) announced on Wednesday that its CyPath Lung test has surpassed sales expectations in the first quarter of 2026, recording a 146% year-over-year increase in unit sales.
CyPath Lung combines flow cytometry with AI to deliver clear “likely” or “unlikely” malignancy results to physicians. Real-world applications suggest the test can detect lung cancer at Stage 1A, improving treatment outcomes, and reduce unnecessary invasive procedures when malignancy risk is low.
“CyPath Lung is designed to address a critical gap in the diagnostic pathway by supporting lung cancer risk assessment, pulmonary nodule management and post-treatment surveillance.”
-Maria Zannes, President and CEO of bioAffinity Technologies
Following the update, bioAffinity stock traded over 8% higher in Wednesday’s premarket.
Get updates to this developing story directly on Stocktwits.